Stockreport

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF – Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently treated with corticosteroids – – Ini [Read more]